Biostax Corp.

US
BTAX
paper.types.company
Rentabilité sur six mois: -99.27%
Rendement en dividendes: 0%

0.0002 $

0 $ 0%
0.0002 $
0.14 $

paper.min_max_per_year

Calendrier des promotions Biostax Corp.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Biostax Corp.

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS).

plus de détails
Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Orlando, Florida.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 0 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA 0 0
ROE 0 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 0 10
Debt/Ratio 0 10
Debt/Equity 0 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 0 0
Rentabilité EPS, % -99.62 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.0002 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 0.0002 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.30d 0.0002 $ 0.0002 $ 0.0002 $ 0 % 0 % 0 %
common.calendar.number_days.90d 0.01 $ 0.0002 $ 0.01 $ -98 % 0 % 0 %
common.calendar.number_days.180d 0.0275 $ 0.0002 $ 0.019 $ -99.27 % 0 % 0 %
common.calendar.number_days.1y 0.036 $ 0.0002 $ 0.14 $ -99.44 % 0 % 0 %
common.calendar.number_days.3y 0 $ 0.0002 $ 0.14 $ 0 % 0 % 0 %
common.calendar.number_days.5y 0 $ 0.0002 $ 0.14 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.0002 $ 0.14 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 0.018 $ 0.0002 $ 0.0159 $ -98.89 % 0 % 0 %

Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Ms. Noreen M. Griffin Founder, Executive VP of Business Development & CEO 1953 (72 année)
Ms. Kelly O'Brien Wilson President 1971 (54 année)
Mr. Glen A. Farmer M.B.A. Chief Financial Officer 1969 (56 années)
Mr. Robert Wilson VP of Strategy & Director 1973 (52 année)
Ms. Cynthia Douglas Company Secretary 1973 (52 année)
Dr. Joseph M. Fortunak Vice President of Global Research & Development and Chemical Development 1955 (70 années)

Informations sur l'entreprise

Adresse: United States, Orlando, 1317 Edgewater Dr. - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.biostaxcorp.com